A detailed history of Pnc Financial Services Group, Inc. transactions in Replimune Group, Inc. stock. As of the latest transaction made, Pnc Financial Services Group, Inc. holds 550 shares of REPL stock, worth $6,875. This represents 0.0% of its overall portfolio holdings.

Number of Shares
550
Previous 550 -0.0%
Holding current value
$6,875
Previous $4,000 50.0%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 09, 2024

SELL
$5.01 - $9.46 $11,252 - $21,247
-2,246 Reduced 80.33%
550 $4,000
Q1 2024

May 10, 2024

BUY
$6.87 - $9.31 $19,098 - $25,881
2,780 Added 17375.0%
2,796 $22,000
Q4 2023

Feb 09, 2024

BUY
$6.75 - $16.18 $108 - $258
16 New
16 $0
Q2 2023

Aug 11, 2023

BUY
$15.65 - $24.1 $1,017 - $1,566
65 New
65 $1,000
Q3 2020

Nov 06, 2020

BUY
$18.85 - $27.0 $18,850 - $27,000
1,000 New
1,000 $23,000

Others Institutions Holding REPL

About Replimune Group, Inc.


  • Ticker REPL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 49,306,700
  • Market Cap $616M
  • Description
  • Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer. The company's lead product candidate is RP1, a selectively replicating version of herpes ...
More about REPL
Track This Portfolio

Track Pnc Financial Services Group, Inc. Portfolio

Follow Pnc Financial Services Group, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Pnc Financial Services Group, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Pnc Financial Services Group, Inc. with notifications on news.